OncoMatch

OncoMatch/Clinical Trials/NCT06215950

A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer

Is NCT06215950 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including CD70 CAR-T cells and CD70 CAR-T cells for ovarian cancer.

Phase 1RecruitingChongqing Precision Biotech Co., LtdNCT06215950Data as of May 2026

Treatment: CD70 CAR-T cells · CD70 CAR-T cellsThis is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic Gynecologic Cancer, and obtain recommended doses and infusion patterns.

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Cervical Cancer

Tumor Agnostic

Biomarker criteria

Required: CD70 overexpression (IHC 3+)

CD70 positive tumor expression (CD70 positive tumor confirmed by histology or pathology (IHC 3+))

Disease stage

Metastatic disease required

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Min 1 prior line

Must have received: standard treatment

Failure or intolerance after standard treatment (disease progression or intolerance such as surgery, chemotherapy, radiotherapy, targeted therapy, etc.), and currently no effective treatment

Cannot have received: anti-CD70 therapy

Received anti-CD70 drug therapy before screening

Lab requirements

Blood counts

neutral granules >1.0×109/l, platelet >75×109/l, hemoglobin >80g/l

Kidney function

serum creatinine ≤2.0×uln

Liver function

alt and ast ≤2.0×uln (patients with liver tumor infiltration can be relaxed to ≤3.0×uln); total bilirubin ≤2.0×uln (gilbert syndrome or liver tumor infiltration can be relaxed to ≤3.0×uln)

Cardiac function

echocardiography indicated cardiac ejection fraction ≥50%, and no obvious abnormality was found in electrocardiogram

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify